Comment on "Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study"

Clin Rheumatol. 2016 Mar;35(3):839-40. doi: 10.1007/s10067-015-2997-8. Epub 2015 Jun 26.

Authors

Florenzo Iannone¹, Elisa Gremese², Gianfranco Ferraccioli³, Giovanni Lapadula⁴; GISEA

Affiliations

¹ Interdisciplinary Department of Medicine, Rheumatology Unit, Bari, Italy. florenzo.iannone@uniba.it.
² Università Cattolica del Sacro Cuore, Rome, Italy. elisa.gremese@rm.unicatt.it.
³ Università Cattolica del Sacro Cuore, Rome, Italy. gf.ferraccioli@rm.unicatt.it.
⁴ Interdisciplinary Department of Medicine, Rheumatology Unit, Bari, Italy. giovanni.lapadula@uniba.it.

PMID: 26113173
DOI: 10.1007/s10067-015-2997-8

No abstract available

Publication types

Letter
Comment

MeSH terms

Adalimumab / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Chemical and Drug Induced Liver Injury / epidemiology*
Etanercept / therapeutic use*
Female
Hepatitis C, Chronic / complications*
Humans
Male

Substances

Antirheumatic Agents
Adalimumab
Etanercept